# Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis

> **NCT03316651** · PHASE2 · UNKNOWN · sponsor: **Dai Huaping** · enrollment: 60 (estimated)

## Conditions studied

- Pulmonary Alveolar Proteinosis
- Treatment

## Interventions

- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT03316651
- **Lead sponsor:** Dai Huaping
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316651, "Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03316651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*